| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) - (BRIGHT) | Autism Spectrum Disorder (ASD) | Phase 3 | Trial Discontinued | Transdermal | Psychiatric |
| Zynerba Pharmaceuticals Inc. | ZYN002 - (CONNECT-FX) | Fragile X Syndrome in Children and Adolescents | Phase 3 | Ongoing | Transdermal | Genetic Disorder |
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) - (BRIGHT) | Autism Spectrum Disorder (ASD) | Phase 3 | Trial Discontinued | Transdermal | Psychiatric |
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) - (RECONNECT) | Fragile X syndrome | Phase 3 | Trial Discontinued | Transdermal | Genetic Disorder |
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) - (INSPIRE) | 22q11.2 Deletion Syndrome | Phase 2 | Ongoing | Transdermal | Genetic Disorder |
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) - (BELIEVE 1) | Developmental and Epileptic Encephalopathies (DEE) | Phase 2 | Trial Discontinued | Transdermal | Neurology |
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) | Adult Epilepsy Patients with Refractory Focal Seizures | Phase 2 | Trial Discontinued | Transdermal | Neurology |
| Zynerba Pharmaceuticals Inc. | Zygel (ZYN002) - STOP | Osteoarthritis | Phase 2 | Trial Discontinued | Transdermal | Orthopedic |